Recombinant Human beta-Galactosidase/GLB1 is produced with our mammalian expression system in human cells. The target protein is expressed with sequence (L24-V677) of Human GLB1 fused with a polyhistidine tag at the C-terminus.
Pureté
> 95 % as determined by reducing SDS-PAGE.
Stérilité
0.2 μm filtered
niveau d'endotoxine
Less than 0.1 ng/μg (1 IEU/μg) as determined by LAL test
GLB1
Origine: Souris
Hôte: Escherichia coli (E. coli)
Recombinant
> 95 %
WB, SDS, Imm, PC
Restrictions
For Research Use only
Format
Liquid
Reconstitution
It is not recommended to reconstitute to a concentration less than 100 μg/mL. Dissolve the lyophilized protein in ddH2O. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Buffer
Supplied as a 0.2 μm filtered solution of 20 mM TrisHCl, 150 mM NaCl, pH 8.0.
Conseil sur la manipulation
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
Stock
-80 °C
Stockage commentaire
Store at < -20°C, stable for 6 months after receipt. Please minimize freeze-thaw cycles.
Beta Galactosidase is a lysosomal beta Galactosidase that hydrolyzes the terminal beta Galactose from Ganglioside and Keratan sulfate. In lysosome, the mature beta Galactosidase protein associates with Cathepsin A and Neuraminidase 1 to form the lysosomal multienzyme complex . An alternative splicing at the RNA level of beta Galactosidase results a catalytically inactive beta Galactosidase that plays an important role in vascular development. Defects of beta-galactosidase (GLB1) are the cause of diseases like GM1-gangliosidosis which is a lysosomal storage disease and Morquio Syndrome B that cause patients to have abnormal elastic fibers. More than 100 mutations have been identified for beta Galactosidase, which result in different residual activities of the mutant enzymes and a spectrum of symptoms in the two related diseases. Alternative Names: Beta-Galactosidase, Acid Beta-Galactosidase, Lactase, Elastin Receptor 1, GLB1, ELNR1